Peptides-based therapy and diagnosis. Strategies for non-invasive therapies in cancer

References

• Kurreck JS. Molecular medicine: an introduction. 1st ed. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2016.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C. Circulating tumor cells: finding rare events for a huge knowledge of cancer dissemination. Cells. 2020;9(3):661.
   Web of Science ®Google Scholar
• Ilie M, Hofman P. Pros: can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res. 2016;5(4):420–423.
   PubMed Web of Science ®Google Scholar
• Loughran CF, Keeling CR. Seeding of tumour cells following breast biopsy: a literature review. Br J Radiol. 2011;84(1006):869–874.
   PubMed Web of Science ®Google Scholar
• Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13(11):795–806.
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–484.
   PubMed Web of Science ®Google Scholar
• Ponnusamy L, Mahalingaiah PK, Singh KP. Chronic oxidative stress increases resistance to doxorubicin-induced cytotoxicity in renal carcinoma cells potentially through epigenetic mechanism. Mol Pharmacol. 2016;89(1):27–41.
   PubMed Web of Science ®Google Scholar
• Senapati S, Mahanta AK, Kumar S, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3:7.
   PubMed Web of Science ®Google Scholar
• Fu X, Shi Y, Qi T, et al. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal Transduct Target Ther. 2020;6(5(1):262.
   Google Scholar
• Roma-Rodrigues C, Pombo I, Raposo L, et al. Nanotheranostics targeting the tumor microenvironment. Front Bioeng Biotechnol. 2019;7:197.
   PubMed Web of Science ®Google Scholar
• Netea-Maier RT, Smit JWA, Netea MG. Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship. Cancer Lett. 2018;413:102–109.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–773.
   PubMed Web of Science ®Google Scholar
• Li M, Yin T, Shi H, et al. Targeting of cance associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol Med Rep. 2016;13(3):2476–2484.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Ricciardi M, Zanotto M, Malpeli G, et al. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br J Cancer. 2015;112(6):1067–1075.
   PubMed Web of Science ®Google Scholar
• Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011;52(2):643–650.
   PubMed Web of Science ®Google Scholar
• Coe D, Begom S, Addey C, et al. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother. 2010;59(9):1367–1377.
   PubMed Web of Science ®Google Scholar
• Lu J. The Warburg metabolism fuels tumor metastasis. Cancer Metastasis Rev. 2019;38(1-2):157–164.
   PubMed Web of Science ®Google Scholar
• Gwangwa MV, Joubert AM, Visagie MH. Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis. Cell Mol Biol Lett. 2018;23:20.
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Chang WA, Huang MS, et al. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem. 2014;2014:351959.
   PubMedGoogle Scholar
• Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2013;64:45–57.
   PubMed Web of Science ®Google Scholar
• Donohoe CL, O'Farrell NJ, Doyle SL, et al. The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol. 2014;7(1):38–50.
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al.; Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–1226.
   PubMed Web of Science ®Google Scholar
• Wang X, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. J Steroid Biochem Mol Biol. 2015;153:35–44.
   PubMed Web of Science ®Google Scholar
• Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36(3):171–198.
   PubMed Web of Science ®Google Scholar
• Venning FA, Wullkopf L, Erler JT. Targeting ECM Disrupts Cancer Progression. Front Oncol. 2016;5:224.
   Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–120.
   PubMed Web of Science ®Google Scholar
• Ricciardelli C, Sakko AJ, Ween MP, et al. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009;28(1-2):233–245.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6(1):11.
   PubMedGoogle Scholar
• Pento JT. Monoclonal antibodies for the treatment of cancer. Anticancer Res. 2017;37(11):5935–5939.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–915.
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
   PubMed Web of Science ®Google Scholar
• Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999;45(9):1628–1650.
   PubMed Web of Science ®Google Scholar
• Sun H, Zhu X, Lu PY, et al. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids. 2014;3:e182.
   PubMedGoogle Scholar
• Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537–550.
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(6):440.
   PubMed Web of Science ®Google Scholar
• Bauer M, Strom M, Hammond DS, et al. Anything you can do, i can do better: can aptamers replace antibodies in clinical diagnostic applications? Molecules. 2019;24(23):4377.
   PubMed Web of Science ®Google Scholar
• Morita Y, Leslie M, Kameyama H, et al. Aptamer therapeutics in cancer: current and future. Cancers (Basel). 2018;10(3):80.
   PubMed Web of Science ®Google Scholar
• Chandola C, Kalme S, Casteleijn MG, et al. Application of aptamers in diagnostics, drug-delivery and imaging. J Biosci. 2016;41(3):535–561.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Colletti A. Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. Br J Pharmacol. 2017;174(11):1378–1394.
   PubMed Web of Science ®Google Scholar
• Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2013;2012:967347.
   Google Scholar
• Ciobanasu C, Kubitscheck U. Cell penetrating peptides targeting and distorting biological membranes. In: Wandelt K, editor. Solid/liquid and biological interfaces. Vol. 7.Weinheim: Wiley-VCH; 2020.
   Google Scholar
• Copolovici DM, Langel K, Eriste E, et al. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8(3):1972–1994.
   PubMed Web of Science ®Google Scholar
• Habault J, Poyet JL. Recent advances in cell penetrating peptide-based anticancer therapies. Molecules. 2019;24(5):927.
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhu JY, Xu XD, et al. Activable cell-penetrating peptide conjugated prodrug for tumor targeted drug delivery. ACS Appl Mater Interfaces. 2015;7(29):16061–16069.
   PubMed Web of Science ®Google Scholar
• Richter M, Zhang H. Receptor-targeted cancer therapy. DNA Cell Biol. 2005;24(5):271–282.
   PubMed Web of Science ®Google Scholar
• Lu K, Duan QP, Ma L, et al. Chemical strategies for the synthesis of peptide-oligonucleotide conjugates. Bioconjug Chem. 2010;21(2):187–202.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149):39–43.
   PubMed Web of Science ®Google Scholar
• Wender PA, Galliher WC, Bhat NM, et al. Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol. 2012;126(1):118–123.
   PubMed Web of Science ®Google Scholar
• Michiue H, Sakurai Y, Kondo N, et al. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials. 2014;35(10):3396–3405.
   PubMed Web of Science ®Google Scholar
• Alves ID, Carre M, Montero MP, et al. A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth. Biochim Biophys Acta. 2014;1838(8):2087–2098.
   PubMed Web of Science ®Google Scholar
• Nakase I, Konishi Y, Ueda M, et al. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J Control Release. 2012;159(2):181–188.
   PubMed Web of Science ®Google Scholar
• Aroui S, Dardevet L, Ben Ajmia W, et al. A Novel platinum-maurocalcine conjugate induces apoptosis of human glioblastoma cells by acting through the ROS-ERK/AKT-p53 pathway. Mol Pharm. 2015;12(12):4336–4348.
   PubMedGoogle Scholar
• Dai L, Liu Y, Liu J, et al. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy. Cancer Lett. 2013;333(1):103–112.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Wei FY, Hide T, et al. Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus. Biomaterials. 2012;33(35):9061–9069.
   PubMed Web of Science ®Google Scholar
• Kim SM, Chae MK, Lee C, et al. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1. Amino Acids. 2014;46(11):2595–2603.
   PubMed Web of Science ®Google Scholar
• Li D, Xu Y. Buforin IIb induced cell cycle arrest in liver cancer. Anim Cells Syst (Seoul)). 2019;23(3):176–183.
   PubMed Web of Science ®Google Scholar
• Cochet O, Kenigsberg M, Delumeau I, et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 1998;58(6):1170–1176.
   PubMed Web of Science ®Google Scholar
• Lim KJ, Sung BH, Shin JR, et al. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One. 2013;8(6):e66084.
   PubMed Web of Science ®Google Scholar
• Orzechowska EJ, Kozlowska E, Czubaty A, et al. Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis. BMC Cancer. 2014;14:771
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):e3015.
   PubMed Web of Science ®Google Scholar
• Golan M, Feinshtein V, David A. Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells. Eur J Pharm Biopharm. 2016;109:103–112.
   PubMed Web of Science ®Google Scholar
• Raad M, Teunissen EA, Mastrobattista E. Peptide vectors for gene delivery: from single peptides to multifunctional peptide nanocarriers. Nanomedicine (Lond)). 2014;9(14):2217–2232.
   PubMed Web of Science ®Google Scholar
• Sato AK, Viswanathan M, Kent RB, et al. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol. 2006;17(6):638–642.
   PubMed Web of Science ®Google Scholar
• Dougherty PG, Sahni A, Pei D. Understanding Cell Penetration of Cyclic Peptides. Chem Rev. 2019;119(17):10241–10287.
   PubMed Web of Science ®Google Scholar
• Lattig-Tunnemann G, Prinz M, Hoffmann D, et al. Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides. Nat Commun. 2011;2:453.
   PubMed Web of Science ®Google Scholar
• Mandal D, Nasrolahi Shirazi A, Parang K. Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters. Angew Chem Int Ed Engl. 2011; 50(41):9633–9637.
   PubMed Web of Science ®Google Scholar
• Reichart F, Horn M, Neundorf I. Cyclization of a cell-penetrating peptide via click-chemistry increases proteolytic resistance and improves drug delivery. J Pept Sci. 2016;22(6):421–426.
   PubMed Web of Science ®Google Scholar
• Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012;6(4):3491–3498.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Levchenko TS, Rammohan R, et al. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A. 2003;100(4):1972–1977.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Huang F, Min X, et al. Protease-responsive prodrug with aggregation-induced emission probe for controlled drug delivery and drug release tracking in living cells. Anal Chem. 2016;88(17):8913–8919.
   PubMed Web of Science ®Google Scholar
• Li Y, Lee RJ, Yu K, et al. Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide. ACS Appl Mater Interfaces. 2016;8(40):26613–26621.
   PubMed Web of Science ®Google Scholar
• Biswas S, Dodwadkar NS, Deshpande PP, et al. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. Eur J Pharm Biopharm. 2013;84(3):517–525.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang B, Luo Z, et al. Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015;7(8):3614–3626.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao Y, Gong J, et al. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. J Control Release. 2014;192:47–56.
   PubMed Web of Science ®Google Scholar
• Gu G, Xia H, Hu Q, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34(1):196–208.
   PubMed Web of Science ®Google Scholar
• Patel SG, Sayers EJ, He L, et al. Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci Rep. 2019;9(1):6298.
   PubMedGoogle Scholar
• Liu S, Yang H, Wan L, et al. Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide Magainin II. Cancer Biother Radiopharm. 2013;28(4):289–297.
   PubMed Web of Science ®Google Scholar
• Veldhoen S, Laufer SD, Restle T. Recent developments in peptide-based nucleic acid delivery. IJMS. 2008;9(7):1276–1320.
   Google Scholar
• Jeong JH, Kim K, Lim D, et al. Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium. PLoS One. 2014;9(1):e80050.
   PubMed Web of Science ®Google Scholar
• Wierzbicki PM, Kogut-Wierzbicka M, Ruczynski J, et al. Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines. Folia Histochem Cytobiol. 2014;52(4):270–280.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang P, Cheetham AG, et al. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release. 2014;191:123–130.
   PubMed Web of Science ®Google Scholar
• Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol (Camb)). 2010;2(7-8):326–337.
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Kotamraju VR, et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA. 2009;106(38):16157–16162.
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18(11):1185–1190.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328(5981):1031–1035.
   PubMed Web of Science ®Google Scholar
• Chen B, He XY, Yi XQ, et al. Dual-peptide-functionalized albumin-based nanoparticles with ph-dependent self-assembly behavior for drug delivery. ACS Appl Mater Interfaces. 2015;7(28):15148–15153.
   PubMed Web of Science ®Google Scholar
• Crisp JL, Savariar EN, Glasgow HL, et al. Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol Cancer Ther. 2014;13(6):1514–1525.
   PubMed Web of Science ®Google Scholar
• Liu Y, Mei L, Xu C, et al. Dual receptor recognizing cell penetrating peptide for selective targeting, efficient intratumoral diffusion and synthesized anti-glioma therapy. Theranostics. 2016;6(2):177–191.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011;5(6):5202–5213.
   PubMed Web of Science ®Google Scholar
• Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA. 2008;105(27):9343–9348.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xie X, Cai X, et al. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials. 2014; 35(14):4368–4381.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xie X, Wang Z, et al. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery. Biomaterials. 2015;48:84–96.
   PubMed Web of Science ®Google Scholar
• Ciobanasu C, Dragomir I, Apetrei A. The penetrating properties of the tumor homing peptide LyP-1 in model lipid membranes. J Pept Sci. 2019;25(3):e3145.
   PubMed Web of Science ®Google Scholar
• Roth L, Agemy L, Kotamraju VR, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene. 2012;31(33):3754–3763.
   PubMed Web of Science ®Google Scholar
• Enback J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans. 2007;35(Pt 4):780–783.
   PubMedGoogle Scholar
• Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA. 2004;101(25):9381–9386.
   PubMed Web of Science ®Google Scholar
• Song N, Zhao L, Zhu M, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019;26(1):363–375.
   PubMed Web of Science ®Google Scholar
• Su CW, Yen CS, Chiang CS, et al. Multistage continuous targeting with quantitatively controlled peptides on chitosan-lipid nanoparticles with multicore-shell nanoarchitecture for enhanced orally administrated anticancer in vitro and in vivo. Macromol Biosci. 2017;17(2):1600260.
   PubMed Web of Science ®Google Scholar
• Yu X, Li A, Zhao C, et al. Ultrasmall semimetal nanoparticles of bismuth for dual-modal computed tomography/photoacoustic imaging and synergistic thermoradiotherapy. ACS Nano. 2017;11(4):3990–4001.
   PubMed Web of Science ®Google Scholar
• Teo P, Wang X, Zhang J, et al. LyP-1-conjugated Fe3O4 nanoparticles suppress tumor growth by magnetic induction hyperthermia. J Biomater Sci Polym Ed. 2018;29(2):181–194.
   PubMed Web of Science ®Google Scholar
• Ren Y, Hauert S, Lo JH, et al. Identification and characterization of receptor-specific peptides for siRNA delivery. ACS Nano. 2012;6(10):8620–8631.
   PubMed Web of Science ®Google Scholar
• Song N, Zhao L, Xu X, et al. LyP-1-modified multifunctional dendrimers for targeted antitumor and antimetastasis therapy. ACS Appl Mater Interfaces. 2020;12(11):12395–12406.
   PubMed Web of Science ®Google Scholar
• Christian S, Pilch J, Akerman ME, et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003;163(4):871–878.
   PubMed Web of Science ®Google Scholar
• Hu Q, Gu G, Liu Z, et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials. 2013;34(4):1135–1145.
   PubMed Web of Science ®Google Scholar
• Moreno P, Ramos-Alvarez I, Moody TW, et al. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets. 2016;20(9):1055–1073.
   PubMed Web of Science ®Google Scholar
• Li X, Taratula O, Schumann C, et al. LHRH-targeted drug delivery systems for cancer therapy. Mini Rev Med Chem. 2017;17(3):258–267.
   PubMed Web of Science ®Google Scholar
• Cao LB, Zeng S, Zhao W. Highly stable PEGylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles for the effective delivery of docetaxel in prostate cancers. Nanoscale Res Lett. 2016;11(1):305.
   PubMed Web of Science ®Google Scholar
• Dadras P, Atyabi F, Irani S, et al. Formulation and evaluation of targeted nanoparticles for breast cancer theranostic system. Eur J Pharm Sci. 2017;97:47–54.
   PubMed Web of Science ®Google Scholar
• Huang CM, Wu YT, Chen ST. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem Biol. 2000;7(7):453–461.
   PubMedGoogle Scholar
• Seitz S, Buchholz S, Schally AV, et al. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anticancer Drugs. 2013;24(2):150–157.
   PubMed Web of Science ®Google Scholar
• Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol. 2015;50(6):740–747.
   PubMed Web of Science ®Google Scholar
• Ahmadpour S, Hosseinimehr SJ. Recent developments in peptide-based SPECT radiopharmaceuticals for breast tumor targeting. Life Sci. 2019;239:116870.
   PubMed Web of Science ®Google Scholar
• Chung EJ, Cheng Y, Morshed R, et al. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 2014;35(4):1249–1256.
   PubMed Web of Science ®Google Scholar
• Okur AC, Erkoc P, Kizilel S. Targeting cancer cells via tumor-homing peptide CREKA functional PEG nanoparticles. Colloids Surf B Biointerfaces. 2016;147:191–200.
   PubMed Web of Science ®Google Scholar
• da Silva WM, de Andrade Alves ESRH, Cipreste MF, et al. Boron nitride nanotubes radiolabeled with 153Sm and 159Gd: potential application in nanomedicine . Appl Radiat Isot. 2020;157:109032.
   PubMed Web of Science ®Google Scholar
• Chen X, Tohme M, Park R, et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging. 2004;3(2):96–104.
   PubMed Web of Science ®Google Scholar
• Deshayes S, Maurizot V, Clochard MC, et al. "Click" conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis. Pharm Res. 2011;28(7):1631–1642.
   PubMed Web of Science ®Google Scholar
• Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264–275.
   PubMed Web of Science ®Google Scholar
• Svensen N, Walton JG, Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol Sci. 2012;33(4):186–192.
   PubMed Web of Science ®Google Scholar
• Fairbrother WJ, Christinger HW, Cochran AG, et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry. 1998;37(51):17754–17764.
   PubMed Web of Science ®Google Scholar
• Qin H, Ding Y, Mujeeb A, et al. Tumor Microenvironment Targeting and Responsive Peptide-Based Nanoformulations for Improved Tumor Therapy. Mol Pharmacol. 2017;92(3):219–231.
   PubMed Web of Science ®Google Scholar
• Wada A, Terashima T, Kageyama S, et al. Efficient prostate cancer therapy with tissue-specific homing peptides identified by advanced phage display technology. Mol Ther Oncolytics. 2019;12:138–146.
   PubMed Web of Science ®Google Scholar
• Lepland A, Asciutto EK, Malfanti A, et al. Targeting pro-tumoral macrophages in early primary and metastatic breast tumors with the CD206-binding mUNO peptide. Mol Pharm. 2020; 617(7):2518–2531.
   PubMedGoogle Scholar
• Pemmari T, Ivanova L, May U, et al. Exposed CendR domain in homing peptide yields skin-targeted therapeutic in epidermolysis bullosa. Mol Ther. 2020;28:1833–1845.
   PubMed Web of Science ®Google Scholar
• Felicio MR, Silva ON, Goncalves S, et al. Peptides with dual antimicrobial and anticancer activities. Front Chem. 2017;5:5.
   PubMed Web of Science ®Google Scholar
• Ahmadpour S, Khodadust F, Hormati A, et al. Pivotal role of peptides in gastric carcinoma: diagnosis and therapy. Int J Pept Res Ther. 2021;27(1):503–525.
   Web of Science ®Google Scholar
• van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112–124.
   PubMed Web of Science ®Google Scholar
• Sharma SV. Melittin resistance: a counterselection for ras transformation. Oncogene. 1992;7(2):193–201.
   PubMed Web of Science ®Google Scholar
• Wu JM, Jan PS, Yu HC, et al. Structure and function of a custom anticancer peptide, CB1a. Peptides. 2009;30(5):839–848.
   PubMed Web of Science ®Google Scholar
• Soballe PW, Maloy WL, Myrga ML, et al. Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer. 1995;60(2):280–284.
   PubMed Web of Science ®Google Scholar
• Baker MA, Maloy WL, Zasloff M, et al. Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res. 1993;53(13):3052–3057.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park CB, Kim JM, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 2008;271(1):47–55.
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim MY, Lee JW, et al. Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker. Peptides. 2011;32(5):895–899.
   PubMed Web of Science ®Google Scholar
• Chen X, Zou X, Qi G, et al. Roles and mechanisms of human cathelicidin LL-37 in cancer. Cell Physiol Biochem. 2018;47(3):1060–1073.
   PubMedGoogle Scholar
• Ren SX, Shen J, Cheng AS, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One. 2013;8(5):e63641.
   PubMed Web of Science ®Google Scholar
• Schröder-Borm H, Bakalova R, Andrä J. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. FEBS Lett. 2005;579(27):6128–6134.
   PubMed Web of Science ®Google Scholar
• Xu N, Wang Y-S, Pan W-B, et al. Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther. 2008;7(6):1588–1597.
   PubMed Web of Science ®Google Scholar
• Aarbiou J, Tjabringa GS, Verhoosel RM, et al. Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37. Inflamm Res. 2006;55(3):119–127.
   PubMed Web of Science ®Google Scholar
• Hubert P, Herman L, Maillard C, et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J. 2007;21(11):2765–2775.
   PubMed Web of Science ®Google Scholar
• Kagan BL, Selsted ME, Ganz T, et al. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci USA. 1990;87(1):210–214.
   PubMed Web of Science ®Google Scholar
• Eliassen LT, Berge G, Leknessund A, et al. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer. 2006;119(3):493–500.
   PubMed Web of Science ®Google Scholar
• Yoo YC, Watanabe S, Watanabe R, et al. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res. 1997;88(2):184–190.
   PubMedGoogle Scholar
• Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 2004;96(13):1015–1022.
   PubMedGoogle Scholar
• Ciobanasu C, Rzeszutek A, Kubitscheck U, et al. NKCS, a mutant of the NK-2 peptide, causes severe distortions and perforations in bacterial, but not human model lipid membranes. Molecules. 2015;20(4):6941–6958.
   PubMed Web of Science ®Google Scholar
• Edison N, Reingewertz TH, Gottfried Y, et al. Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells. Clin Cancer Res. 2012;18(9):2569–2578.
   PubMed Web of Science ®Google Scholar
• Lundy FT, Orr DF, Gallagher JR, et al. Identification and overexpression of human neutrophil alpha-defensins (human neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. Oral Oncol. 2004;40(2):139–144.
   PubMed Web of Science ®Google Scholar
• Richardson A, de Antueno R, Duncan R, et al. Intracellular delivery of bovine lactoferricin's antimicrobial core (RRWQWR) kills T-leukemia cells. Biochem Biophys Res Commun. 2009;388(4):736–741.
   PubMed Web of Science ®Google Scholar
• Calvo Tardon M, Allard M, Dutoit V, et al. Peptides as cancer vaccines. Curr Opin Pharmacol. 2019;47:20–26.
   PubMed Web of Science ®Google Scholar
• Kuai R, Ochyl LJ, Bahjat KS, et al. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16(4):489–496.
   PubMed Web of Science ®Google Scholar
• Sultan H, Kumai T, Nagato T, et al. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol Immunother. 2019;68(3):455–466.
   PubMed Web of Science ®Google Scholar
• Karkada M, Berinstein NL, Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics. 2014;8:27–38.
   PubMedGoogle Scholar
• Bijker MS, van den Eeden SJ, Franken KL, et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179(8):5033–5040.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180(1):347–352.
   PubMed Web of Science ®Google Scholar
• Ahsan A, Ramanand SG, Bergin IL, et al. Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts. Neoplasia. 2014;16(2):105–114.
   PubMed Web of Science ®Google Scholar
• Wiedermann U, Wiltschke C, Jasinska J, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 2010;119(3):673–683.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Wesolowski R, Ahn DH, et al. Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors. Clin Cancer Res. 2019;25(12):3495–3507.
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842–854.
   PubMed Web of Science ®Google Scholar